Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cel-Sci Corporation Common Stock (NY:CVM)

9.160 +0.170 (+1.89%)
Official Closing Price Updated: 4:10 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cel-Sci Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Files Request With the UK’s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Why CEL-SCI (CVM) Shares Are Down 20%
CEL-SCI Corporation (NASDAQ: CVM) shares are trading lower by 21.3% to $2.25 Tuesday morning after the company priced its public offering of 2.5 million shares at $2.00 per share. 
Via Benzinga
CEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results
From CEL-SCI Corporation
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
  On Monday, 27 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 59 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 56 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday morning, 70 companies achieved new lows for the year. 
Via Benzinga
CEL-SCI Announces Closing of Public Offering
From CEL-SCI Corporation
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) gained 90% to $0.3560 after the company issued strategic update and announced restructuring. 
Via Benzinga
US Stocks Mixed; Bank of America Tops Q2 Views
U.S. stocks traded mixed this morning, with the Dow Jones gaining around 70 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.20% to 34,655.10 while the NASDAQ fell 0.38% to... 
Via Benzinga
TDOC Stock Alert: Teladoc Doubles Down on Microsoft AI Partnership
Teladoc (TDOC) stock is on the move Tuesday as the company expands its Microsoft (MSFT) AI partnership to enhance Teladoc Health Solo. 
Via InvestorPlace
CMG Stock Alert: Chipotle Announces International Expansion Plan
Chipotle Mexican Grill (CMG) stock is in the news Tuesday after the restaurant chain announced plans for an international expansion. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why Is CEL-SCI (CVM) Stock Down 23% Today?
CEL-SCI (CVM) stock is dropping on Tuesday after the biotechnology company announced details of a public share offering. 
Via InvestorPlace
Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
Gainers Biophytis S.A. (NASDAQ: BPTS) shares surged 53.9% to $3.31 in pre-market trading after the company signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the company's... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start off trading for Tuesday with a breakdown of the biggest pre-market stock movers worth watching this morning. 
Via InvestorPlace
CEL-SCI Announces Pricing of Public Offering
From CEL-SCI Corporation
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
CEL-SCI Announces Proposed Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Concludes Positive Meeting With U.S. FDA Concerning Multikine’s Approval for Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine’s Increased Efficacy and Points to Potential for Combination With Checkpoint Inhibitors for Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
CEL-SCI to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer—New Patent to Be Filed
From CEL-SCI Corporation
Via Business Wire
Why CEL-SCI Shares Are Shooting Higher Today
CEL-SCI Corporation (NYSE: CVM) announced that the latest results from its pivotal Phase 3 study of Multikine, a presurgical cancer immunotherapy, were presented at the European Society for... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI’s Multikine Significantly Prolonged Overall Survival in Head & Neck Cancer—Phase 3 Data Presented at ESTRO 2023
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Financial Results
From CEL-SCI Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.